Science Corp. raises $400 million to take its PRIMA retinal implant to the US
The Series D, reportedly at a $3.5 billion valuation, funds PRIMA's wider European rollout, a planned US launch through the FDA's Humanitarian Device Exemption and Science's biohybrid brain interface program.
Science Corporation announced on November 17, 2026 that it has raised a $400 million Series D. Investors include Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech; the company did not name a lead investor. Science says it has now raised more than $900 million since it was founded in 2021. The company did not disclose a valuation, but TechCrunch, citing a person familiar with the deal, reported $3.5 billion, up from about $1.5 billion at its $230 million Series C in March.
What the money is for
Science says the funds will go to four areas: making PRIMA available in more European countries, preparing a US launch, expanding research, manufacturing and operations, and a large investment in its biohybrid program, a neural interface that combines engineered neurons with the brain’s own circuits.
PRIMA is a tiny wireless chip implanted under the retina and paired with camera glasses that project images onto it as near-infrared light. It is meant for people who have lost central vision to geographic atrophy, an advanced form of dry age-related macular degeneration. It received a CE mark in Europe in July, and trial participants have kept their reading gains for three years. In the US, Science is pursuing approval through the FDA’s Humanitarian Device Exemption, a pathway for devices that treat rare conditions.
Why it matters
- This is one of the largest private rounds in neurotechnology this year, and it follows Precision Neuroscience’s $250 million round in September.
- PRIMA is one of the few implanted neural interfaces already sold commercially, so investors are backing a product with revenue, not only a research program.
- Caveats: a US decision is still pending, and the Humanitarian Device Exemption limits how many patients can be treated each year. The biohybrid interface has not yet been tested in people.
Learn more: Visual prosthesis · Science Corp.